INDV (Indivior Pharmaceuticals) ROCE %: 138.44% (As of Mar. 2026)


INDV Indivior Pharmaceuticals Inc INDV
75 GF Score
Price $41.48
GF Value $22.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals ROCE %?

Indivior Pharmaceuticals INDV +3.80% 75 ROCE % is 138.44% as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 75/100 and a GF Value™ of $22.99 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Indivior Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 138.44%.

Indivior Pharmaceuticals  (NAS:INDV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Indivior Pharmaceuticals ROCE % Related Terms

Indivior Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals ROCE % Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.04 -6.97 -18.03 14.15 83.65

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.54 80.42 46.28 94.31 138.44
INDV
75GF Score
Indivior Pharmaceuticals Inc INDV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals ROCE % Calculation

Indivior Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=284/( ( (1316 - 924) + (1201 - 914) )/ 2 )
=284/( (392+287)/ 2 )
=284/339.5
=83.65 %

Indivior Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=488/( ( (1201 - 914) + (1197 - 779) )/ 2 )
=488/( ( 287 + 418 )/ 2 )
=488/352.5
=138.44 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 138.44% mean?
Indivior Pharmaceuticals (INDV) has a ROCE % of 138.44% as of Mar. 2026.
Is Indivior Pharmaceuticals' ROCE % too high?
Indivior Pharmaceuticals' current ROCE % is 138.44%. The Drug Manufacturers industry median ROCE % is 7.00. Indivior Pharmaceuticals' value of 138.44% is 1879.1% above this industry median. Overall, Indivior Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' ROCE % compare to AMRX and KNSA?
Indivior Pharmaceuticals' ROCE % of 138.44% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Indivior Pharmaceuticals' value of 138.44% is 1879.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current ROCE % of 138.44% is 1879.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current ROCE % is 138.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.99, compared to a current price of $41.48 — trading 80.4% above its estimated fair value. The current ROCE % is 138.44% and 1879.1% above the Drug Manufacturers industry median of 7.00. Indivior Pharmaceuticals' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current ROCE % is 138.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.48 is trading 80.4% above its estimated GF Value™ of $22.99. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • ROCE %: 138.44%
  • GF Value™: $22.99 vs. price of $41.48 (80.4% above fair value)
  • GF Score™: 75/100 with 6 warning signs
  • Industry Position: 1879.1% above the Drug Manufacturers median

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
75GF Score

Get the complete analysis for INDV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.48
Price
$22.99
GF Value